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Background: The study aimed to determine the short and long-term effects of exercise training on exercise capacity
and health-related quality of life (HRQoL) compared to usual care in people with dust-related pleural and interstitial
respiratory diseases. No previous studies have specifically evaluated exercise training in this patient population.
Methods: Participants with a diagnosis of a dust-related respiratory disease including asbestosis and asbestos related
pleural disease were recruited and randomised to an eight-week exercise training group (EG) or a control group (CG) of
usual care. Six-minute walk distance (6MWD), St George’s Respiratory Questionnaire (SGRQ) and Chronic Respiratory
Disease Questionnaire (CRQ) were measured at baseline, eight weeks and 26 weeks by an assessor blinded to
group allocation.
Results: Thirty-three of 35 male participants completed the study. Sixty-nine percent of participants had asbestos
related pleural disease. At eight weeks, compared to the CG, the EG showed a significantly increased 6MWD
(mean difference (95%CI)) 53 metres (32 to 74), improved SGRQ total score, -7 points (-13 to -1) and increased
CRQ total score, 6.4 points (2.1 to 10.7). At 26 weeks significant between-group differences were maintained in
6MWD, 45 metres (17 to 73) and CRQ total score, 13.1 points (5.2 to 20.9).
Conclusion: Exercise training improved short and long-term exercise capacity and HRQoL in people with dust-related
pleural and interstitial respiratory diseases.
Clinical trial registration number: ANZCTR12608000147381. Date trial registered: 27.03.2008.
Keywords: Asbestosis, Diffuse pleural thickening, Interstitial lung disease, Exercise, Pulmonary rehabilitation, Physical
activity, Health-related quality of lifeBackground
Dust-related pleural and interstitial respiratory diseases
are a global health problem. Past and ongoing exposure
to harmful dusts continue to impact millions of people
worldwide [1-3] with the prevalence of some dust-related re-
spiratory diseases increasing [4]. The pathological changes
of these diseases include parenchymal and/or pleural fibrosis
which may result in shortness of breath at rest or on exer-
tion, reduced exercise capacity and health-related quality of
life (HRQoL) [5-8]. Limited treatment options are available* Correspondence: maritad@uni.sydney.edu.au
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tory diseases [3,9].
Interstitial lung disease (ILD) describes a broad range
of diseases with diverse aetiologies including idiopathic
pulmonary fibrosis (IPF). Recently, exercise training has
been shown to improve exercise capacity and HRQoL in
people with ILD, predominantly IPF [10,11]. While there
is an indication from uncontrolled or mixed-disease stud-
ies that exercise training may benefit people with dust-
related interstitial respiratory diseases [12,13], no studies
using rigorous randomised controlled trial methodology
have investigated the effect of exercise training on exercise
capacity and HRQoL in people with dust-related pleural
and interstitial respiratory diseases.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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outcomes in people with chronic respiratory diseases.
Higher levels of physical activity are associated with health
benefits for people with chronic obstructive pulmonary
disease (COPD), including greater exercise capacity and a
higher single breath diffusing capacity for carbon monox-
ide (DLCO) [14]. Conversely, lower levels of physical activ-
ity are associated with increased morbidity and mortality
[15]. The effect of exercise training on physical activity
levels in people with dust-related pleural and interstitial
respiratory diseases is unknown.
The primary aims of this study were to determine the
short and long-term effects of exercise training compared
to usual care on exercise capacity and HRQoL in people
with dust-related pleural and interstitial respiratory dis-
eases. The secondary aims were to determine whether
exercise training improved symptoms and habitual daily
physical activity compared to usual care in people with
dust-related pleural and interstitial respiratory diseases.
Methods
Study design
The study was a multi-centred, assessor blinded, parallel
group, randomised controlled trial and was conducted in
New South Wales, Australia between January 2009 and
July 2011. After enrolment into the study and collection
of baseline measures, participants were randomly allo-
cated to either an exercise group (EG) or control group
(CG) by a person independent of the recruitment process
through a computer-generated randomisation programme.
Random allocation with minimisation for disease type
(asbestos related pleural disease or other), severity
(FVC <80% or ≥80%) and training centre was used.
The study was approved by the Human Research Ethics
Committee of Sydney South West Area Health Service
and all participants gave written informed consent. The
trial was registered with the Australian and New Zealand
Clinical Trials Registry (ANZCTR12608000147381).
Participants
Participants were recruited through the Workers’ Com-
pensation Dust Diseases Board (DDB) of New South Wales,
Australia, respiratory physicians, support groups, workers’
unions and newsletters for returned servicemen. Both
males and females were eligible to participate if they had a
medical diagnosis of a non-malignant dust-related pleural
or interstitial respiratory disease including asbestosis,
silicosis and asbestos related pleural disease (defined as
diffuse pleural thickening and/or rounded atelectasis).
Diagnosis had been established by the participant’s re-
spiratory physician or by the DDB Medical Authority which
is a panel of respiratory physicians with specialist know-
ledge in occupational lung disease. The diagnostic process
included an occupational history, clinical examination by aphysician, radiological findings on chest X-ray and com-
puted tomography scans confirming dust-related pleural
and/or interstitial disease, and lung function (spirometry
and lung volumes via plethysmography) as previously
described [16].
People were excluded from the study if they had meso-
thelioma; discrete parietal pleural plaques as their only
manifestation of dust exposure; cardiovascular, neurological
or orthopaedic conditions limiting exercise performance;
were on long term oxygen therapy; could not understand
English; or had participated in a pulmonary rehabilitation
programme within the last 12 months.Intervention
The EG participated in individually prescribed exercise
training at one of seven pulmonary rehabilitation pro-
grammes. All participants completed supervised aerobic
exercise training, including both walk and cycle training,
three times weekly for eight weeks. The training mode,
intensity and duration were based on the recommended
guidelines for COPD [17]. For walking training the exer-
cise intensity was 80% of the average walking speed of
the better baseline six-minute walk test (6MWT) and for
cycle training the initial intensity was 60% of peak work
rate achieved on the incremental cycle test (ICT). Inten-
sity was progressed weekly by increments of 5% of the
average walking speed or the peak work achieved on the
ICT, or if dyspnoea or rate of perceived exertion (RPE)
scores (whichever was highest) was less than three on the
modified Borg 0-10 scale [18] during an exercise training
session. Participants completed a minimum of 15 minutes
walking and 15 minutes cycling at each session in the first
training week, progressing to 30 minutes of each modality
by the final week. Rest periods were permitted as required.
Adherence with training was pre-defined as completion of
at least 80% of training sessions. Exercise training did not
include strength training and there was no education
component. At the completion of the eight week train-
ing the EG was not provided with any further advice or
guidance on continuing exercise training. The CG did
not receive any exercise intervention and continued
with their usual medical management for the duration
of the study.Pulmonary function
Participants performed spirometry and lung volumes
(body plethysmography) at baseline and eight weeks and
DLCO at baseline only (SensorMedics, Yorba Linda, Ca,
USA). Spirometry was also measured at 26 weeks follow-
ing the intervention period. All tests were performed ac-
cording to standard protocols [19] and results expressed
as a percentage of the predicted values [19-21].
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All participants attended Royal Prince Alfred Hospital
(RPAH), Sydney, Australia, for testing at baseline, imme-
diately following eight weeks of exercise training or usual
care and again after a further 26 weeks. All outcomes were
measured by the same assessor, blinded to group allocation.
The primary outcomes for the study were exercise capacity
measured by the six-minute walk distance (6MWD)
and HRQoL measured by the Chronic Respiratory Dis-
ease Questionnaire (CRQ) total score and the St George’s
Respiratory Questionnaire (SGRQ) total score. Secondary
outcomes were peak work rate achieved on the ICT,
endurance cycle time, CRQ dyspnoea, fatigue, emotional
function and mastery domain scores, SGRQ symptoms,
activity and impact domain scores and physical activity
measured by an activity monitor. Whilst all primary and
secondary outcomes were determined at baseline and
eight weeks following the interventions, only 6MWD,
HRQoL and physical activity outcomes were measured
after a further 26 weeks.Exercise capacity
Participants performed two six-minute walk tests (6MWT
1 and 6MWT 2) according to guidelines [22] on a con-
tinuous 32-metre oval track at baseline, immediately
following the exercise training or eight weeks of usual
care period and again after a further 26 weeks. Tests were
separated by a minimum of 30 minutes or until heart rate
and oxygen saturation had returned to resting values.
On a separate day, participants performed a symptom-
limited ICT and endurance cycle test (ECT) on an
electromagnetically-braked cycle ergometer (Lode BV,
Groningen, The Netherlands). Tests were separated by a
minimum of one hour or until heart rate and oxygen satur-
ation had returned to resting values. For the ICT, work rate
was increased every minute by a predetermined amount,
ranging from 5 to 20 Watts.min-1 according to the partici-
pant’s self-reported exercise capacity and clinical judge-
ment so that test duration was approximately 10 minutes
[23]. For the ECT, work rate was increased to 40% peak
work rate in the first minute and to 80% peak work rate
from the second minute to symptom-limited test termin-
ation [24]. During the ICT and ECT participants wore a
face mask and breath-by-breath measures for oxygen
uptake (VO2) and carbon dioxide output (VCO2) were
obtained (Vmax Encore, SensorMedics, Yorba Linda, USA).
Heart rate and SpO2 were simultaneously measured using a
pulse oximeter (Radical™, Masimo Corporation, Irvine,
USA). Dyspnoea and RPE scores were recorded each
minute and at peak work rate using the modified Borg
0-10 scale [18]. Peak work rate from the ICT was com-
pared to predicted normal values [25]. The ICT and ECT
were only performed at baseline and eight weeks.Health-related quality of life (HRQoL)
Participants completed the Chronic Respiratory Disease
Questionnaire (CRQ) and the St George’s Respiratory
Questionnaire (SGRQ) in random order at baseline, eight
and 26 weeks. Both questionnaires have previously been
used to evaluate HRQoL in ILD [7]. The minimal import-
ant difference (MID) for improvements in HRQoL in
people with dust-related pleural and interstitial respiratory
diseases has not been established. However, in people with
COPD, a change of 0.5 in the mean score per item for the
CRQ (calculated by dividing the overall score by the num-
ber of questions) has been established as the (MID) [26]. If
the actual scores, rather than mean score, are used, the
MIDs for each domain are 2.5 for dyspnoea, 2 for fatigue,
3.5 for emotional function, 2 for mastery, and 10 for the
CRQ total score. For the SGRQ, the MID is a reduction of
four points in the SGRQ total score for people with
COPD.
Physical activity
Physical activity was measured using an activity monitor
(SenseWear Pro3 Armband, BodyMedia, Pittsburgh, PA,
USA) worn for seven consecutive days when not attend-
ing for exercise testing at baseline, eight and 26 weeks.
Participants were instructed to wear the activity monitor
continuously, removing it only when showering or swim-
ming. Steps per day, metabolic equivalents (METs) and en-
ergy expenditure were recorded using the SenseWear
Professional software Version 6.1. Compliance was set
at a minimum wear time of >85% per day for at least three
days [27]. If this level of compliance was not achieved, the
data were excluded from analysis.
Statistical analysis
Data were analysed according to the intention-to-treat
principle. Statistical analysis was performed on PASW-
Windows (release 18.0; PASW, Chicago, IL, USA). All
baseline data are expressed as mean (standard deviation
(SD)). We used an analysis of covariance (ANCOVA) for
the primary and secondary endpoints. The ANCOVA model
included the outcome measure at baseline as the covariate
and the repeat outcome measure (at eight or 26 weeks) and
treatment allocation as the fixed factors. The data are
presented as mean (95% confidence interval). The level
of significance was set at a p-value of <0.05.
Sample size
Due to the paucity of data on exercise training in dust-
related ILD and no data on exercise training in people
with pleural disease, the sample size was based on out-
comes of exercise training in people with ILD (without
IPF) [10]. Twenty-six participants were required to give
the study a statistical power of 80% to detect a difference
between groups in 6MWD following exercise training of
Table 1 Baseline characteristics, disease type, exercise
capacity and health-related quality of life of the study
participants
Exercise training group Control group
n =18 n =17
Mean (SD) Mean (SD)
Age, yr 70 (7) 72 (6)
Height, cm 170 (5) 175 (6)
Weight, kg 80 (13) 85 (11)
BMI, kg/m2 27 (4) 28 (3)
ARPD 11 13
Asbestosis 3 2





FVC, L 3.4 (0.9) 3.5 (0.8)
FVC, % pred 86 (23) 86 (18)
FEV1, L 2.1 (0.6) 2.4 (0.6)
FEV1, % pred 75 (23) 81 (16)
FEV1/FVC, % 64 (11) 69 (7)
FEV1/FVC, % pred 88 (16) 95 (10)
TLC, % pred 83 (20) 79 (15)
FRC, % pred 82 (28) 77 (15)
RV, % pred 77 (34) 72 (19)
DLCO, % pred 54 (15) 57 (13)
KCO, % pred 77 (22) 82 (19)
Smoking history, pack year 18 (18) 16 (25)
6MWD, m 474 (77) 469 (81)
SGRQ Total 30 (15) 29 (19)
SGRQ Activity 42 (21) 42 (28)
SGRQ Symptoms 38 (19) 32 (20)
SGRQ Impacts 20 (14) 20 (17)
CRQ Total 105 (13) 100 (13)
CRQ Dyspnoea 17 (7) 20 (6)
CRQ Fatigue 20 (5) 21 (3)
CRQ Emotional Function 40 (7) 40 (6)
CRQ Mastery 23 (4) 23 (4)
Average daily steps 7897 (2557) 8347 (3981)
Average daily EE, cal 2373 (349) 2660 (521)
Average daily METs 1.3 (0.1) 1.3 (0.2)
n = number; SD = standard deviation; yr = year; cm = centimetre; kg = kilogram;
BMI = body mass index; m =metre; ARPD = asbestos related pleural disease;
FVC = forced vital capacity; L = litre; % pred = percentage of predicted value;
FEV1 = forced expiratory volume in one second; TLC = total lung capacity;
FRC = functional residual capacity; RV = residual volume; DLCO = diffusing
capacity for carbon monoxide; KCO = carbon monoxide transfer coefficient;
6MWD= six-minute walk distance; SGRQ = St George’s Respiratory Questionnaire;
CRQ = Chronic Respiratory Disease Questionnaire; EE = energy expenditure;
cal = calorie; MET = metabolic equivalent.
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25% loss to follow-up.
Results
Participants
Forty-four male participants were assessed with 35 in-
cluded in the study. Of these 35 participants, 24 (69%) had
asbestos related pleural disease (ARPD), five (14%) had
asbestosis, three (9%) had silicosis, two (6%) had com-
bined ARPD and asbestosis, and one (3%) had mixed-
dust pneumoconiosis. Thus the majority of participants
had pleural not parenchymal lung disease. Only two
participants had any evidence of COPD on high resolution
computed tomography (HRCT) scan. The reasons for non-
inclusion of nine participants were pain affecting exercise
performance (two), neurological impairment (two), unstable
cardiovascular responses during exercise testing (two),
parietal pleural plaques only (one), peripheral vascular
disease affecting exercise performance (one) and an in-
ability to understand English (one). Baseline character-
istics of the 35 participants and the diagnoses of study
participants are shown in Table 1. There were no differ-
ences between the groups at baseline.
At eight weeks, 34 participants completed the 6MWT
and the HRQoL questionnaires, 33 completed the ICT
and the ECT and 31 completed the physical activity mea-
surements. At 26 weeks, 31 participants completed the
6MWT, 33 completed the HRQoL questionnaires and 30
completed the physical activity measurements. The flow
of participants is presented in Figure 1. There was no sig-
nificant change in FVC during the study (p = 0.823). No
adverse events were reported during the exercise training.
Participants in the EG attended a mean (SD) of 20 (5)
exercise training sessions. Fifteen participants were ad-
herent with the exercise training sessions and three par-
ticipants were non-adherent, attending three, nine and
17 training sessions respectively. The effects of exercise
training on 6MWD at eight weeks are shown in Table 2
and Figure 2 and at 26 weeks are shown in Table 3 and
Figure 2. The 6MWD was significantly greater in the EG
compared to the CG at eight weeks, mean difference
53 m (95% CI 32 to 74). At 26 weeks the mean (SD)
6MWD for the EG was 525 (81) metres and for the CG
was 466 (101) metres. There was a between group differ-
ence in the change in 6MWD from baseline to 26 weeks
of 45 m (95% CI 17 to 73) (p = 0.003) which was signifi-
cant in favour of the EG (Figure 2).
At eight weeks, peak work rate and endurance cycle
time were significantly greater in the EG than the CG
(Table 2). In addition, at eight weeks, heart rate at iso-
work rate on the ICT was significantly lower in the
EG than the CG and Borg dyspnoea score at isotime
on the ECT was significantly lower in the EG than the
CG (Table 2).
Figure 1 Participant flow.
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the CG at eight weeks (Table 3). The CRQ total score and
domain scores for dyspnoea, emotional function and mas-
tery and the SGRQ total and symptoms scores demon-
strated significantly improved scores in the EG compared
to the CG at eight weeks. At 26 weeks, the difference be-
tween groups in the CRQ total score and CRQ domains
were maintained. However, there were no differences be-
tween groups in the SGRQ domains at 26 weeks (Table 3).
There were small statistically significant improvements
in measures of physical activity (average daily steps and
average daily METs) at eight weeks in the EG compared
to the CG (Table 3). Although the improvement in average
daily METs was maintained at 26 weeks in the EG, the dif-
ference between groups was very small, 0.11 METs (95%
CI 0.03 to 2.0). At 26 weeks there was no significant differ-
ence in average daily steps between the EG and the CG.Discussion
This is the first randomised controlled trial to examine
the effects of exercise training on exercise capacity and
HRQoL in people with dust-related pleural and interstitial
respiratory diseases. This study demonstrated improvements
in exercise capacity and HRQoL immediately following an
exercise training programme compared to a control group
of usual care, with improvements in the exercise training
group sustained at 26 weeks following intervention.
Exercise training improved functional exercise capacity
measured by an increase of 53 metres in 6MWD in this
cohort of people with dust-related pleural and interstitial
respiratory diseases. This magnitude of change was larger
than the 20 to 35 metre improvements reported in people
with ILD [10,11] and similar to the 48 metre improve-
ment after exercise training in people with COPD [28].
In our study, the improvement in 6MWD was maintained
Table 2 Mean (SD) of groups, mean (SD) difference within groups, mean (95% CI) difference between groups for
exercise capacity immediately following intervention
Group Difference within group Difference between groups
Week 0 Week 8 Week 8 minus week 0 Week 8 minus week 0 ANCOVA
Mean (SD) Mean (SD) Mean (SD) Mean difference (95% CI) p Value
6MWT EG CG EG CG EG CG
n = 18 n = 17 n = 17 n = 17 n = 17 n = 17
6MWD, m 475 (79) 469 (81) 548 (72) 489 (83) 73 (29) 20 (32) 53 (32 to 74) <0.0001*
ICT EG CG EG CG EG CG
n = 18 n = 17 n = 16 n = 17 n = 16 n = 17
Peak work rate, W 108 (41) 110 (33) 116 (43) 107 (30) 8 (7) -4 (12) 12 (5 to 19) 0.002*
VO2peak, L/min 1.6 (0.5) 1.6 (0.4) 1.6 (0.5) 1.6 (0.4) 0.1 (0.1) 0.1 (0.3) -0.01 (-0.16, 0.14) 0.882
VEpeak, L/min 56 (21) 55 (12) 59 (24) 55 (13) 3 (7) 0.3 (11) 2.84 (-4.13, 9.80) 0.412
HR at peak work rate, bpm 121 (22) 123 (13) 120 (23) 126 (12) -0.5 (8) 3 (11) -4 (-11, 3) 0.238
VE at isowork, L/min 56 (21) 52 (12) 55 (24) 53 (13) -0.6 (5) 1.3 (8) -2 (-7, 3) 0.411
HR at isowork, bpm 121 (22) 119 (11) 117 (21) 122 (13) -4 (9) 3 (8) -7 (-13, -0.3) 0.040*
Borg dyspnoea at isowork 4 (2) 3(2) 4(2) 4(2) 0 (2) 1 (2) -0.5 (-1.6, 0.6) 0.366
RPE at isowork 4 (3) 4 (2) 4 (2) 5 (2) -0.4 (2) 0.2 (2) -0.5 (-1.6, 0.5) 0.315
ECT EG CG EG CG EG CG
n = 18 n = 17 n = 16 n = 17 n = 16 n = 17
Endurance cycle time, seconds 319 (130) 311 (80) 534 (268) 308 (113) 216 (254) -3 (113) 222 (84, 360) 0.003*
VE at isotime, L/min 51 (15) 53 (13) 50 (15) 52 (12) -0.1 (5) -1 (10) 0.6 (-5, 6) 0.824
Borg dyspnoea at isotime 5 (2) 3 (2) 3 (2) 4 (2) -1 (2) 1 (2) -1.2 (-2.3, -0.04) 0.043*
Borg dyspnoea at test end 5 (3) 4 (2) 5 (2) 5 (2) -0.2 (1) 1 (2) -1.1 (-2.3, 0.1) 0.076
RPE at isotime 5 (3) 5 (2) 4 (3) 5 (2) -1 (2) -0.3 (2) -0.9 (-2.2, 0.3) 0.148
SD = standard deviation; CI = confidence interval; ANCOVA = analysis of covariance; 6MWT = six minute walk test; EG = exercise training group; CG = control group;
n = number; 6MWD = six minute walk distance; m =metre; ICT = incremental cycle test; W = watts; VO2peak = peak oxygen uptake; L/min = litres per minute;
VEpeak =minute ventilation at peak work rate; HR = heart rate; bpm = beats per minute; VE = minute ventilation; RPE = rate of perceived exertion; ECT = endurance
cycle test; *p <0.05.
Figure 2 Change in six-minute walk distance (6MWD). Data are
means and standard errors. *p < 0.05, exercise training group (EG)
versus control group (CG).
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ing without ongoing supervised exercise. This finding dif-
fers from the study by Holland et al where improvements
in 6MWD were not maintained at 26 weeks in people with
ILD, predominantly IPF [10]. One possible explanation is
that our cohort included participants with mild to moder-
ate dust-related pleural and interstitial respiratory diseases
rather than more severe ILD. Our participants also had
relatively stable disease over the study period, as evident
by the stability of the FVC over 26 weeks, compared to the
significant decline in FVC over a similar period in the
study by Holland et al, indicating the progressive and
severe nature of ILD in their cohort.
Exercise training also resulted in improvements in peak
and endurance exercise capacity. Compared to the CG, the
EG achieved a mean improvement of 12 watts in peak ex-
ercise capacity and a significant reduction in heart rate of 7
beats/minute at isowork rate. In the absence of changes to
ventilatory parameters, these findings indicate that cardio-
vascular and peripheral muscle adaptations consistent with
known training effects occurred. Participants in the EG
Table 3 Differences between the exercise training and control groups immediately following intervention and
26 weeks following intervention for exercise capacity, health-related quality of life and physical activity
Outcome Week 8 minus week 0 ANCOVA Week 26 minus week 0 ANCOVA
Mean difference p Value Mean difference p Value
(95% CI) (95% CI)
Exercise capacity n = 34 n = 31
6MWD, m 53 (32, 74) <0.001* 45 (17, 73) 0.003*
HRQoL n = 34 n = 33
SGRQ Total -7 (-13, -1) 0.033* -4 (-12, 4) 0.293
SGRQ Symptoms -15 (-27, -2) 0.021* -4 (-18, 9) 0.530
SGRQ Activity -5 (-13, 3) 0.209 -4 (-15, 8) 0.505
SGRQ Impacts -5 (-12, 2) 0.183 -4 (-12, 5) 0.383
CRQ Total 6.4 (2.1, 10.7) 0.005* 13.1 (5.2 to 20.9) 0.002*
CRQ Dyspnoea 2.2 (0.6, 3.7) 0.007* 3.4 (1.5, 5.4) 0.001*
CRQ Fatigue 1.3 (-0.02, 2.6) 0.053 2.9 (0.6, 5.2) 0.015*
CRQ Emotional Function 2.4 (0.7, 4.2) 0.008* 5.5 (2.0, 8.9) 0.003*
CRQ Mastery 1.4 (0.1, 2.7) 0.036* 2.7 (1.0, 4.3) 0.002*
Physical activity n = 31 n = 30
Average daily steps 1514 (15, 3012) 0.048* 1206 (-156, 2568) 0.08
Average daily EE, cal 86 (-57, 230) 0.227 158 (-8, 323) 0.062
Average daily METs 0.08 (0.01, 0.15) 0.038* 0.11 (0.03, 0.20) 0.012*
CI = confidence interval; ANCOVA = analysis of covariance; n = number; 6MWD = six-minute walk distance; m =metre; HRQoL = health-related quality of life;
SGRQ = St George’s Respiratory Questionnaire; CRQ = Chronic Respiratory Disease Questionnaire; EE = energy expenditure; cal = calorie; MET =metabolic equivalent.
*p <0.05.
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mean improvement of 222 seconds in endurance cycle
time following exercise training and a reduction of per-
ceived breathlessness at endurance isotime, which has
not been previously reported in people with ILD. There-
fore, exercise training in people with dust-related pleural
and interstitial respiratory diseases yielded a similar im-
provement in endurance exercise capacity as those with
COPD who demonstrated improvements in endurance
cycle time of 198 (352) seconds following an exercise
training programme [29].
The minimal important difference for improvements
in exercise capacity in people with dust-related pleural and
interstitial respiratory diseases has not been determined.
However, the improvement in 6MWD in the EG in our
study was considerably greater than the reported MID of
35 metres for the 6MWT in people with COPD [30] and
the MID ranging from 29-34 metres in people with diffuse
parenchymal lung disease [31]. The improvements in
endurance cycle time and peak work rate in people with
dust-related pleural and interstitial respiratory diseases
were also greater than the MID ranging from 100-200
seconds [29] and 3-5 watts [32] respectively in people
with COPD. Therefore, the use of a similar exercise train-
ing regimen for people with dust-related pleural and inter-
stitial respiratory diseases, as has been previously used in
COPD [17], resulted in improvements in exercise capacitythat exceeded the MID established for people with COPD
or other ILD.
Important improvements in HRQoL were achieved in
people with dust-related pleural and interstitial respiratory
diseases immediately following exercise training. The
improvement in SGRQ total score was greater than the
clinically important reduction of 4 points for people with
COPD [33]. Despite statistically significant improvements
in the CRQ total score and domains of dyspnoea and
emotional function, these improvements did not reach the
MID established for COPD. Twenty-six weeks following
the intervention the significant difference between groups
was maintained and interestingly the values of the EG
group increased further and reached the MID in all do-
mains of the CRQ. The improvements in HRQoL occurred
with exercise training, in the absence of an education com-
ponent, as has previously been shown in COPD [34]. This
study has also demonstrated that the SGRQ and CRQ,
which are disease specific questionnaires originally de-
signed to assess HRQoL in people with COPD, can also
be used to detect changes in HRQoL in people with dust-
related pleural and interstitial respiratory diseases.
This is the first study to evaluate the effects of exercise
training on levels of daily physical activity in people with
dust-related pleural and interstitial respiratory diseases. In
epidemiological studies, higher levels of physical activity
have been associated with health benefits in people with
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pleural respiratory diseases. Our study demonstrated small
but significant improvements in physical activity after ex-
ercise training compared to a control group of usual care,
both in the short-term (eight weeks) and the longer term
(26 weeks). A recent meta-analysis demonstrated a very
small increase in physical activity after exercise training
in people with COPD [35]. Although the improvement
in average daily METs in our study was maintained fol-
lowing exercise training in the longer term, the small
magnitude of improvement questions the clinical rele-
vance of this finding. More research is needed to identify
how best to improve activity levels in this patient popula-
tion and whether improvements in physical activity are
associated with improved health outcomes.
The development of dust-related pleural and intersti-
tial respiratory diseases is characterized by a long latency
period from exposure to dust to development of disease
[3]. Consequently, the mean age of participants was 71 years.
With increasing age, the FEV1/FVC ratio decreases. While
the mean FEV1/FVC ratio in our participants was less than
0.7, FEV1/FVC ratio as a percent of predicted was within
the normal range for people of this age [21] and did not re-
flect the presence of COPD. The HRCT findings further
confirmed that only two participants had any evidence of
COPD. Thus the findings of this study are specifically
related to asbestos-related and other dust-related respira-
tory disease and are not confounded by co-existing COPD.
The original sample size calculation was based on out-
comes of exercise training in people with ILD. As the
study progressed, two distinct participant groups became
evident, participants with dust-related pleural disease
and participants with dust-related interstitial lung disease.
To account for this heterogeneity, more participants
were recruited than originally calculated.
There are several limitations to this study. Incremental
and endurance cycle ergometry tests were not repeated
at 26 weeks thus it is unknown whether improvements
in peak and endurance exercise capacity shown at eight
weeks were maintained in the longer term. In addition,
participants did not complete resistance training as part
of the exercise training therefore the effects of resistance
training in this population remain unclear. While recruit-
ment was open to males and females, only males volun-
teered to participate in the study, so the findings cannot
be extrapolated to females with dust-related respiratory
diseases. Since our study population did not include
people with dust-related pleural and interstitial respira-
tory diseases who were on long term oxygen therapy and
as our participants did not have severe disease, the findings
of our study cannot be extrapolated to such sub-groups.
Finally, there was some heterogeneity in the diagnoses
of study participants which limit the generalisation of
the findings. More studies of each specific disease groupare needed to address the paucity of literature on the spe-
cific effects of exercise training in people with dust-related
pleural disease and dust-related interstitial lung disease.
Such diseases usually have a slower progression than other
ILDs and thus interventions such as exercise training that
improve exercise capacity, quality of life and levels of daily
physical activity may have an important role in the man-
agement of these diseases that previously have had few
effective therapies.
Conclusion
This randomised controlled trial demonstrated that exer-
cise training improved short and long-term exercise cap-
acity and health-related quality of life in people with
dust-related pleural and interstitial respiratory diseases.
Commonly, people with dust-related pleural and intersti-
tial respiratory diseases have not been considered appro-
priate for referral to pulmonary rehabilitation programmes
due to the lack of evidence of benefit. This study has
provided compelling evidence for the benefits of exercise
training in people with dust-related pleural and interstitial
respiratory diseases and for the inclusion of this population
in pulmonary rehabilitation programmes.
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